Second Sight Medical Products (Second Sight Medical Products) 5-Year EBITDA Growth Rate : 50.40% (As of Jun. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Second Sight Medical Products 5-Year EBITDA Growth Rate?

Second Sight Medical Products's EBITDA per Share for the three months ended in Jun. 2022 was $0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 79.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 50.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Second Sight Medical Products was 79.80% per year. The lowest was -95.30% per year. And the median was 22.40% per year.

Competitive Comparison of Second Sight Medical Products's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Second Sight Medical Products's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Second Sight Medical Products's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Second Sight Medical Products's 5-Year EBITDA Growth Rate falls into.

Second Sight Medical Products 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Second Sight Medical Products (NAS:EYESW) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Second Sight Medical Products 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Second Sight Medical Products's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Second Sight Medical Products (Second Sight Medical Products) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Second Sight Medical Products Inc (NAS:EYESW) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

13170 Telfair Avenue, Sylmar, CA, USA, 91342

Website

https://www.secondsight.com

Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.